Cognitive impairment in heart failure
dc.creator | Dardiotis, E. | en |
dc.creator | Giamouzis, G. | en |
dc.creator | Mastrogiannis, D. | en |
dc.creator | Vogiatzi, C. | en |
dc.creator | Skoularigis, J. | en |
dc.creator | Triposkiadis, F. | en |
dc.creator | Hadjigeorgiou, G. M. | en |
dc.date.accessioned | 2015-11-23T10:25:12Z | |
dc.date.available | 2015-11-23T10:25:12Z | |
dc.date.issued | 2012 | |
dc.identifier | 10.1155/2012/595821 | |
dc.identifier.issn | 20900597 | |
dc.identifier.uri | http://hdl.handle.net/11615/26926 | |
dc.description.abstract | Cognitive impairment (CI) is increasingly recognized as a common adverse consequence of heart failure (HF). Although the exact mechanisms remain unclear, microembolism, chronic or intermittent cerebral hypoperfusion, and/or impaired cerebral vessel reactivity that lead to cerebral hypoxia and ischemic brain damage seem to underlie the development of CI in HF. Cognitive decline in HF is characterized by deficits in one or more cognition domains, including attention, memory, executive function, and psychomotor speed. These deficits may affect patients' decision-making capacity and interfere with their ability to comply with treatment requirements, recognize and self-manage disease worsening symptoms. CI may have fluctuations in severity over time, improve with effective HF treatment or progress to dementia. CI is independently associated with disability, mortality, and decreased quality of life of HF patients. It is essential therefore for health professionals in their routine evaluations of HF patients to become familiar with assessment of cognitive performance using standardized screening instruments. Future studies should focus on elucidating the mechanisms that underlie CI in HF and establishing preventive strategies and treatment approaches. © Copyright 2012 Efthimios Dardiotis et al. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84863637384&partnerID=40&md5=3c9c7fd85ca7c1a4806c831b6b03c7e2 | |
dc.subject | antiarrhythmic agent | en |
dc.subject | cardiotonic agent | en |
dc.subject | cholinesterase inhibitor | en |
dc.subject | digoxin | en |
dc.subject | dipeptidyl carboxypeptidase inhibitor | en |
dc.subject | diuretic agent | en |
dc.subject | Alzheimer disease | en |
dc.subject | artificial heart pacemaker | en |
dc.subject | attention | en |
dc.subject | blood vessel reactivity | en |
dc.subject | bradycardia | en |
dc.subject | brain hypoxia | en |
dc.subject | brain ischemia | en |
dc.subject | brain perfusion | en |
dc.subject | cognitive defect | en |
dc.subject | cognitive rehabilitation | en |
dc.subject | decision making | en |
dc.subject | dementia | en |
dc.subject | depth perception | en |
dc.subject | disability | en |
dc.subject | disease severity | en |
dc.subject | executive function | en |
dc.subject | heart failure | en |
dc.subject | heart transplantation | en |
dc.subject | language disability | en |
dc.subject | memory | en |
dc.subject | microembolism | en |
dc.subject | mortality | en |
dc.subject | multiinfarct dementia | en |
dc.subject | pathophysiology | en |
dc.subject | physical activity | en |
dc.subject | priority journal | en |
dc.subject | psychomotor performance | en |
dc.subject | review | en |
dc.subject | self care | en |
dc.subject | transcranial magnetic stimulation | en |
dc.subject | working memory | en |
dc.title | Cognitive impairment in heart failure | en |
dc.type | journalArticle | en |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |